Abstract: Diagnostic devices comprising: an inlet for receiving a solution comprising a biological sample comprising a target nucleic acid molecule; at least one reaction chamber, comprising a nuclease for cleaving a nucleic acid molecule, into a first portion bonded to a marker and a second portion bonded to a bulky molecule; a membrane in liquid connection to the at least one reaction chamber, having porosity sized to filter the first portion from the solution containing the second portion; and an informative chamber configured to receive the filtered first portion, having at least one of, a transparent region showing a visible marker; and a detector for detecting the marker are provided. Methods of using the devices to detect a target nucleic acid molecule in a sample are also provided.

Abstract: The present invention is directed to, inter alia, a method for identifying a reference macromolecule for which a variant having improved function can be identified and/or engineered. Further provided is a macromolecule variant, such as, but not limited to Cas protein variant(s), being characterized by having improved function compared to a reference, and a method for designing same.

Abstract: Diagnostic devices comprising: an inlet for receiving a solution comprising a biological sample comprising a target nucleic acid molecule; at least one reaction chamber, comprising a nuclease for cleaving a nucleic acid molecule, into a first portion bonded to a marker and a second portion bonded to a bulky molecule; a membrane in liquid connection to the at least one reaction chamber, having porosity sized to filter the first portion from the solution containing the second portion; and an informative chamber configured to receive the filtered first portion, having at least one of, a transparent region showing a visible marker; and a detector for detecting the marker are provided. Methods of using the devices to detect a target nucleic acid molecule in a sample are also provided.

Abstract: A method of treating Parkinson's Disease (PD) characterized by the presence of a mutant allele of leucine-rich repeat kinase 2 (LRRK2) gene in a subject is disclosed. The method comprises administering to the subject a CRISPR-Cas system guide RNA (gRNA) which specifically binds to the mutant allele of said leucine-rich repeat kinase 2 (LRRK2) gene and a CRISPR endonuclease, thereby treating the Parkinson's Disease (PD).

Abstract: The invention relates to improvement and therapy of neuronal conditions involving neurodegenerative, inflammatory and vascular conditions. More specifically, the invention provides compositions and methods for specific targeted elimination of apolipoprotein E4 (apoE4), and uses thereof in the treatment and prevention of ApoE4 associated conditions.